^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    FHVH-BCMA-T

    i
    Other names: T-cells targeting B-cell maturation antigen, FHVH-BCMA-T, FHVH-BCMA-T cells
    Associations

    News

    Trials
    Company:
    National Cancer Institute
    Drug class:
    BCMA-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    12ms
    Rapid anti-myeloma activity by T cells expressing an anti-BCMA CAR with a human heavy-chain-only antigen-binding domain. (PubMed, Mol Ther)
    The CAR was designated FHVH33-CD8BBZ...Anti-CAR antibody responses were detected in 4/12 patients assessed. FHVH-T have powerful, rapid, and durable anti-MM activity.
    Journal • IO biomarker
    |
    CD4 (CD4 Molecule) • CCR7 (Chemokine (C-C motif) receptor 7)
    |
    CD8 expression • CCR7 expresion
    |
    FHVH-BCMA-T
    2years
    T Cells Expressing a Fully-Human Anti-BCMA Chimeric Antigen Receptor with a Heavy-Chain-Only Antigen-Recognition Domain Exhibit Rapid and Durable Activity Against Multiple Myeloma (ASH 2022)
    The CAR containing FHVH33 is called FHVH33-CD8BBZ...Twenty-five patients received 300 mg/m2 of cyclophosphamide and 30 mg/m2 of fludarabine on days -5 to -3 followed by infusion of FHVH-T on day 0...FHVH-T therapy led to durable responses with most anti-myeloma activity occurring within 14 days after FHVH-T infusion. Blood levels of FHVH-T correlated with CD4+CCR7+ infusion cells.
    IO biomarker
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • IL6 (Interleukin 6) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • IL2 (Interleukin 2) • IL10 (Interleukin 10) • CCR7 (Chemokine (C-C motif) receptor 7) • IL15 (Interleukin 15)
    |
    CD8 expression
    |
    cyclophosphamide • fludarabine IV • FHVH-BCMA-T
    3years
    Treatment of Patients with T Cells Expressing a Fully-Human Anti-BCMA CAR with a Heavy-Chain Antigen-Recognition Domain Caused High Rates of Sustained Complete Responses and Relatively Mild Toxicity (ASH 2021)
    The treatment protocol was 300 mg/m 2 of cyclophosphamide and 30 mg/m 2 of fludarabine on days -5 to -3 followed by infusion of FHVH33-T on day 0...Five patients received tocilizumab and 4 patients received corticosteroids for CRS...Two of the biopsied plasmacytomas were BCMA+, and two were BCMA-negative by immunohistochemistry. FHVH33-CD8BBZ CAR T cells caused relatively mild toxicity and a high rate of sCRs in patients with relapsed MM including MM with low cell-surface BCMA expression.
    Clinical • IO biomarker
    |
    CD8 (cluster of differentiation 8)
    |
    cyclophosphamide • fludarabine IV • Actemra IV (tocilizumab) • FHVH-BCMA-T